Does LAPATINIB DITOSYLATE Cause Second primary malignancy? 18 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 18 reports of Second primary malignancy have been filed in association with LAPATINIB DITOSYLATE (Lapatinib). This represents 0.5% of all adverse event reports for LAPATINIB DITOSYLATE.
18
Reports of Second primary malignancy with LAPATINIB DITOSYLATE
0.5%
of all LAPATINIB DITOSYLATE reports
6
Deaths
4
Hospitalizations
How Dangerous Is Second primary malignancy From LAPATINIB DITOSYLATE?
Of the 18 reports, 6 (33.3%) resulted in death, 4 (22.2%) required hospitalization.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for LAPATINIB DITOSYLATE. However, 18 reports have been filed with the FAERS database.
What Other Side Effects Does LAPATINIB DITOSYLATE Cause?
Diarrhoea (893)
Death (665)
Nausea (317)
Fatigue (301)
Vomiting (259)
Rash (249)
Drug ineffective (183)
Malignant neoplasm progression (183)
Off label use (141)
Disease progression (137)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which LAPATINIB DITOSYLATE Alternatives Have Lower Second primary malignancy Risk?
LAPATINIB DITOSYLATE vs LAPINE T-LYMPHOCYTE IMMUNE GLOBULIN
LAPATINIB DITOSYLATE vs LARONIDASE
LAPATINIB DITOSYLATE vs LAROTRECTINIB
LAPATINIB DITOSYLATE vs LASILIX
LAPATINIB DITOSYLATE vs LASIX